Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 2-3, 2010, Pages 202-214

  Pathak, Shriram M ^a   Udupa, N ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Bioavailability; Morin; P glycoprotein; Talinolol

Indexed keywords

GLYCOPROTEIN P; MORIN; TALINOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG TRANSPORT; ILEUM; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; NONHUMAN; PROTEIN INTERACTION; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; FLAVONOIDS; HUMANS; INTESTINAL ABSORPTION; P-GLYCOPROTEIN; PROPANOLAMINES; RATS; RATS, WISTAR;

EID: 77951034037     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.703     Document Type: Article

References (28)

1. Conseil G, Baubichon-Cortary H, Dayan G, Jault JM, Barron D, Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 1998; 95: 9831-9836. (Pubitemid 28415255)
2. Cermak R, Wolffram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab 2006; 7: 729-744. (Pubitemid 44509679)
3. Francis AR, Shetty TK, Bhattacharya RK. Modulating effect of plant flavonoids on the mutagenicity of N-methyl-N-nitro-N-nitrosoguanidine. Carcinogenesis 1989; 10: 1953-1955. (Pubitemid 19244876)
4. Hanasaki Y, Ogawa S, Fukui S. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic Biol Med 1994; 16: 845-850. (Pubitemid 24193534)
5. Fang SH, Hou YC, Chang WC, Hsiu SL, Chao PD, Chiang BL. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci 2003; 74: 743-756.
6. Choi JS, Han HK. Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats. Arch Pharm Res 2005; 28: 970-976.
7. Choi HJ, Choi JS, Han HK. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Arch Pharm Res 2005; 28: 970-976.
8. Li X, Yun JK, Choi JS. Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos 2007; 28: 151-156. (Pubitemid 46730923)
9. Piao YJ, Choi JS. Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. J Pharm Pharmacol 2008; 60: 625-629. (Pubitemid 351589050)
10. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450, 3A and P-glycoprotein: implications for drug delivery in cancer chemotherapy. Mol Carcinogen 1995; 13: 129-134.
11. Spahn-Langguth H, Baktir G, Radschuweit A et al. P-Glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 1998; 36: 16-24. (Pubitemid 28031804)
12. Hilgendorf C, Spahn-Langguth H, Langguth P. Intestinal secretion of talinolol: competitive and P-gp-antibody-induced inhibition of transport in studies with Caco-2 cells. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: R-453.
13. Iida A, Tomita M, Hayashi M. Regional difference in P-glycoprotein function in rat intestine. Drug Metab Pharmacokinet 2005; 20: 100-106.
14. Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J Pharm Sci 2006; 95: 1984-1993. (Pubitemid 44433029)
15. 2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther 1999; 288: 171-178.
16. Stephens RH, O'Neill CA, Bennett J et al. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice. Br J Pharmacol 2002; 135: 2038-2046. (Pubitemid 34478317)
17. Troutman MD, Thakker DR. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 2003; 20: 1210-1224.
18. Varma MV, Panchagnula R. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J Pharm Sci 2005; 94: 1694-1704. (Pubitemid 41360864)
19. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13: 1336-1342. (Pubitemid 26344978)
20. Hanafy A, Langguth P, Spahn-Langguth H. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur J Pharm Sci 2001; 12: 405-415. (Pubitemid 32166739)
21. Heinz Diehl K, Hull D, Morton D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001; 21: 15-23.
22. Food and Drug Administration (FDA). Guidance for Industry Bioanalytical Method Validation. Department of Health and Human Services: Rockville, MD, 2001.
23. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 1595-1599. (Pubitemid 37268274)
24. Siegmund W, Ludwig K, Engel G, et al. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J Pharm Sci 2003; 92: 604-610. (Pubitemid 36258975)
25. Yamazaki M, Neway WE, Ohe T et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 2001; 296: 723-735.
26. Shirasaka Y, Li Y, Shibue Y, et al. Concentration-dependent effect of naringin on intestinal absorption of β1-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res 2009; 26: 560-567.
27. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 2000; 38: 161-167. (Pubitemid 30193611)
28. Mols R, Brouwers J, Schinkel AH, Annaert P, Augustijns P. Intestinal perfusion with mesenteric blood sampling in wild-type and knockout mice: evaluation of a novel tool in biopharmaceutical drug profiling. Drug Metab Dispos 2009; 37: 1334-1337.